close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

NIMH STAR*D Findings Could Redefine Treatment for Depression

NIMH STAR*D Findings Could Redefine the Way America Views, Seeks and Receives Treatment for Depression

Second Trial Phase Results Emphasize Individualized Treatment

ALEXANDRIA, Va., March 23, 2006 -- Two studies released in The New England Journal of Medicine today provide strong scientific support that treatment for depression works and should be provided on a tailored, individualized basis. As the largest-of-its-kind research study on depression treatments, the National Mental Health Association (NMHA) looks to the Sequenced Treatment Alternatives to Relieve Depression, or STAR*D, trials to help redefine the way Americans view depression-as an illness that requires proper medical care, customized to the individual, without the stigma and misunderstanding often attached.

"The second phase of results of STAR*D, as released by the National Institute of Mental Health, strongly affirms that treatment works and should be individualized for recovery," said Cynthia Wainscott, acting president and CEO of NMHA. "With these significant findings, America is stepping out of the dark ages and into a new era where depression, one of our nation's formidable foes, will be more commonly viewed as a medical issue and not shunned as a weakness of character."

Reducing the barriers to care is crucial. Science needs to inform and enhance the line of communication between healthcare providers and consumers as they work towards recovery. Without needed treatment, individuals with depression can face a range of painful outcomes: difficulty at work and in relationships; substance abuse; other physical and mental health problems; and even suicide, which claims 30,000 American lives each year. To help individuals overcome depression, a range of treatments must be available. The best treatment plan is one decided on by a consumer, in partnership with his or her healthcare provider, based on the unique characteristics and needs of the individual.

"I know from personal experience that different treatments work for different people," said Dianne Dorlester, who lives with depression. "I had symptoms of depression for several years and treatment without medication was successful at times. I was resistant to taking medications because I felt I should be able to recover without them. When my depression became so severe that I could barely function, I finally began taking an anti-depressant in addition to talk therapy. This has allowed me to get my life back."

"While NMHA is encouraged by the STAR*D findings and commends NIMH for conducting this important study, it is vital that NIMH not stop here," added Wainscott. "We are concerned about the lack of research focused on differences in how people of different genders, races and ethnicities respond to treatment. We strongly urge NIMH to broaden its scope of research to include more culturally and ethnically diverse participants."

The findings released this week represent only the second of four phases of the STAR*D research study.

NMHA mental health experts and individuals receiving treatment for depression are available for comment by calling (703) 797-2588.

The National Mental Health Association is the country's oldest and largest nonprofit organization addressing all aspects of mental health and mental illness. With more than 340 affiliates nationwide, NMHA works to improve the mental health of all Americans through advocacy, education, research and service.

Source: NIMH STAR*D Findings Could Redefine the Way America Views, Seeks and Receives Treatment for Depression The National Mental Health Association

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...